“This week we announced a definitive agreement with Regeneron Pharmaceuticals to acquire Decibel, which we believe reflects the tremendous promise of gene therapy for hearing loss,” said Laurence Reid, Ph.D., Chief Executive Officer of Decibel. “We remain highly focused on executing on the CHORD clinical trial and excited by the potential benefit that DB-OTO may provide to people with otoferlin-related hearing loss. With six active clinical trial sites at prestigious institutions across three countries, we continue to work towards our goal of addressing this unmet medical need.”
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DBTX:
- Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update
- Decibel Therapeutics downgraded to Neutral from Outperform at Baird
- Decibel Therapeutics downgraded to Hold from Buy at JonesResearch
- Decibel Therapeutics (NASDAQ:DBTX) Skyrockets On Acquisition By Regeneron
- Decibel Therapeutics downgraded to Neutral from Buy at H.C. Wainwright